Daniel Truong

Summary

Affiliation: The Parkinson's and Movement Disorder Institute
Country: USA

Publications

  1. ncbi request reprint Botulinum toxin: clinical use
    Daniel D Truong
    The Parkinson s and Movement Disorder Institute, 9940 Talbert Avenue, Fountain Valley, CA 92708, USA
    Parkinsonism Relat Disord 12:331-55. 2006
  2. ncbi request reprint Management of non-motor symptoms in advanced Parkinson disease
    Daniel D Truong
    The Parkinson s and Movement Disorder Institute, 9940 Talbert Avenue, Fountain Valley, CA 92708, USA
    J Neurol Sci 266:216-28. 2008
  3. pmc Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm
    Daniel D Truong
    Parkinson s and Movement Disorder Institute, 9940 Talbert Avenue, Fountain Valley, California, 92708, USA
    J Neural Transm (Vienna) 120:1345-53. 2013
  4. doi request reprint Botulinum toxins in the treatment of primary focal dystonias
    Daniel Truong
    Parkinson s and Movement Disorder Institute, 9940 Talbert Avenue, Suite 204, Fountain Valley, CA 92708, USA
    J Neurol Sci 316:9-14. 2012
  5. pmc High-throughput mutational analysis of TOR1A in primary dystonia
    Jianfeng Xiao
    Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA
    BMC Med Genet 10:24. 2009
  6. doi request reprint Evidence for the effectiveness of botulinum toxin for sialorrhoea
    D D Truong
    The Parkinson s and Movement Disorder Institute, Fountain Valley, CA 92708, USA
    J Neural Transm (Vienna) 115:631-5. 2008
  7. doi request reprint Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia
    Daniel Truong
    The Parkinson s and Movement Disorder Institute, 9940 Talbert Avenue, 204, Fountain Valley, CA 92708, USA
    Parkinsonism Relat Disord 16:316-23. 2010
  8. ncbi request reprint Current clinical applications of botulinum toxin
    Daniel D Truong
    The Parkinson s and Movement Disorder Institute, Orange Coast Memorial Medical Center, Fountain Valley, California, USA
    Curr Pharm Des 15:3671-80. 2009
  9. pmc Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease
    Daniel D Truong
    The Parkinson s and Movement Disorder Institute, Fountain Valley, CA 92708, USA
    Clin Interv Aging 4:109-13. 2009
  10. doi request reprint Recognition and management of Parkinson's disease during the premotor (prodromal) phase
    Daniel D Truong
    The Parkinson s and Movement Disorder Institute, Orange Coast Memorial Medical Center, 9940 Talbert Ave, Fountain Valley, CA, USA
    Expert Rev Neurother 9:847-57. 2009

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Botulinum toxin: clinical use
    Daniel D Truong
    The Parkinson s and Movement Disorder Institute, 9940 Talbert Avenue, Fountain Valley, CA 92708, USA
    Parkinsonism Relat Disord 12:331-55. 2006
    ..Many other indications are currently under investigation, including gastroenterologic and urologic indications, analgesic management and migraine. This paper is an extensive review of the spectrum of BoNT clinical applications...
  2. ncbi request reprint Management of non-motor symptoms in advanced Parkinson disease
    Daniel D Truong
    The Parkinson s and Movement Disorder Institute, 9940 Talbert Avenue, Fountain Valley, CA 92708, USA
    J Neurol Sci 266:216-28. 2008
    ..They are often less appreciated than motor symptoms but are important sources of disability for many PD patients. This review describes these non-motor symptoms and their managements...
  3. pmc Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm
    Daniel D Truong
    Parkinson s and Movement Disorder Institute, 9940 Talbert Avenue, Fountain Valley, California, 92708, USA
    J Neural Transm (Vienna) 120:1345-53. 2013
    ....
  4. doi request reprint Botulinum toxins in the treatment of primary focal dystonias
    Daniel Truong
    Parkinson s and Movement Disorder Institute, 9940 Talbert Avenue, Suite 204, Fountain Valley, CA 92708, USA
    J Neurol Sci 316:9-14. 2012
    ..Because each BoNT product is developed from distinct purification and manufacturing procedures and has varying toxin complex size and structures, physicians need to be aware of these differences when choosing an agent...
  5. pmc High-throughput mutational analysis of TOR1A in primary dystonia
    Jianfeng Xiao
    Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA
    BMC Med Genet 10:24. 2009
    ..The aim of this study was to identify TOR1A Exon 5 mutations in a large cohort of subjects with mainly non-generalized primary dystonia...
  6. doi request reprint Evidence for the effectiveness of botulinum toxin for sialorrhoea
    D D Truong
    The Parkinson s and Movement Disorder Institute, Fountain Valley, CA 92708, USA
    J Neural Transm (Vienna) 115:631-5. 2008
    ..According to this scheme, the effectiveness of botulinum toxin A in the treatment of sialorrhoea is considered established (level A). Botulinum toxin B is considered probably effective in the treatment of sialorrhoea (level B)...
  7. doi request reprint Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia
    Daniel Truong
    The Parkinson s and Movement Disorder Institute, 9940 Talbert Avenue, 204, Fountain Valley, CA 92708, USA
    Parkinsonism Relat Disord 16:316-23. 2010
    ..These results confirm that Dysport (500 units) is safe, effective, and well-tolerated in patients with CD...
  8. ncbi request reprint Current clinical applications of botulinum toxin
    Daniel D Truong
    The Parkinson s and Movement Disorder Institute, Orange Coast Memorial Medical Center, Fountain Valley, California, USA
    Curr Pharm Des 15:3671-80. 2009
    ....
  9. pmc Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease
    Daniel D Truong
    The Parkinson s and Movement Disorder Institute, Fountain Valley, CA 92708, USA
    Clin Interv Aging 4:109-13. 2009
    ..Tolcapone produces expected dopaminergic side effects, including headache, nausea, insomnia, as well as diarrhea; however, these side effects are generally mild and as a rule do not result in discontinuation of therapy...
  10. doi request reprint Recognition and management of Parkinson's disease during the premotor (prodromal) phase
    Daniel D Truong
    The Parkinson s and Movement Disorder Institute, Orange Coast Memorial Medical Center, 9940 Talbert Ave, Fountain Valley, CA, USA
    Expert Rev Neurother 9:847-57. 2009
    ..Both symptomatic and disease-modifying agents applicable in the premotor phase of PD will also be addressed...
  11. ncbi request reprint Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations
    D D Truong
    The Parkinson s and Movement Disorder Institute, Fountain Valley, CA 92708, USA
    Eur J Neurol 13:36-41. 2006
    ..Other applications of botulinum toxin in the larynx include spasmodic laryngeal dyspnea and voice tremors. We also review injection techniques, the different toxin types used, and toxin doses...
  12. ncbi request reprint Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study
    Daniel Truong
    The Parkinson s and Movement Disorders Institute, Fountain Valley, California 92708, USA
    Mov Disord 20:783-91. 2005
    ..These results confirm previous reports that Dysport (500 units) is safe, effective, and well-tolerated in patients with cervical dystonia...
  13. doi request reprint Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial
    Daniel Truong
    The Parkinson s and Movement Disorder Institute, Orange Coast Memorial Medical Center, 9940 Talbert Ave 204, Fountain Valley, CA 92708, USA
    Parkinsonism Relat Disord 14:407-14. 2008
    ..The best balance of sustained efficacy and favorable safety profile was provided by 80 units of Dysport/eye in this study...
  14. ncbi request reprint Case studies in the advancement of Parkinson's disease
    Karen Frei
    Parkinson s and Movement Disorder Institute, Orange Coast Memorial Medical Center, Fountain Valley, CA, USA
    CNS Spectr 13:1-6. 2008
    ..This Expert Review Supplement presents three cases that illustrate different aspects of Parkinson's disease, including diagnosis, non-motor symptoms, and treatment...
  15. ncbi request reprint Activation of adenosine triphosphate-sensitive potassium channels confers protection against rotenone-induced cell death: therapeutic implications for Parkinson's disease
    Kwok Keung Tai
    The Parkinson s and Movement Disorder Institute, Long Beach Memorial Medical Center, California 90806, USA
    J Neurosci Res 69:559-66. 2002
    ....
  16. ncbi request reprint Expanding use of botulinum toxin
    Roongroj Bhidayasiri
    Department of Neurology, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Neurol Sci 235:1-9. 2005
    ....
  17. ncbi request reprint Natural history of posttraumatic cervical dystonia
    Karen P Frei
    The Parkinson s and Movement Disorder Institute, Fountain Valley, California 92708, USA
    Mov Disord 19:1492-8. 2004
    ..Based on our observations of these cases, we propose that complex regional pain syndrome (CRPS) could represent a variant of posttraumatic cervical dystonia that may develop over time after the initiation of dystonia...
  18. ncbi request reprint Motor complications in Parkinson disease: clinical manifestations and management
    Roongroj Bhidayasiri
    Chulalongkorn Comprehensive Movement Disorders Center, Division of Neurology, Chulalongkorn University Hospital, Bangkok 10330, Thailand
    J Neurol Sci 266:204-15. 2008
    ..Better understanding of these potential complications will result in better management of these problems and lessen the disability associated with advanced PD...
  19. doi request reprint Botulinum toxins revisited
    Daniel D Truong
    J Neural Transm 115:557. 2008
  20. ncbi request reprint Post-hypoxic myoclonus induces Fos expression in the reticular thalamic nucleus and neurons in the brainstem
    Kwok Keung Tai
    The Parkinson s and Movement Disorder Research Laboratory, Long Beach Memorial Medical Center, CA 90806, USA
    Brain Res 1059:122-8. 2005
    ..The results suggest that neuronal activity in the RT and the MLF plays a contributing role in post-hypoxic myoclonus...
  21. ncbi request reprint Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD
    Robert A Hauser
    Department of Neurology, University of South Florida, and Tampa General Healthcare, 33606, USA
    Neurology 61:297-303. 2003
    ..To evaluate the safety and efficacy of the adenosine A(2A) receptor antagonist istradefylline (KW-6002) in patients with levodopa-treated Parkinson's disease (PD) with both motor fluctuations and peak-dose dyskinesias...